best recombinant dna technology market, recombinant dna technology industry, global recombinant dna technology market, recombinant dna technology market outlook, recombinant dna technology market trends, recombinant dna technology market growth.
What Is The Current And Future Market Size Analysis of the Recombinant DNA Technology Market?
The recombinant DNA technology market size has exhibited strong growth in recent years. It is projected to expand from $858.94 billion in 2024 to $920.82 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. Such robust growth in the historic period can be attributed to factors such as increasing healthcare demands, growth of the biopharmaceutical industry, rising investments in R&D, and the emergence of personalized medicine.
The recombinant DNA technology market size is expected to continue this robust growth trajectory in the coming years. It is projected to reach $1,318.72 billion by 2029, reflecting a compound annual growth rate (CAGR) of 9.4%. This forecasted growth can be attributed to rising chronic diseases, the emergence of biotech startups, increased funding in biotech, and the globalization of biotech markets, along with consumer acceptance, and education. Major trends in the forecast period include scientific advancements, gene editing advancements, cell and gene therapies, development of RNA therapeutics, therapeutic applications in rare diseases, and AI and data integration.
Get Your Free Sample of The Global Recombinant DNA Technology Market Report:
What Factors Are Driving The Growth of the Recombinant DNA Technology Market?
The significant rise in the number of chronic diseases is a key driver of the recombinant DNA technology market. Chronic diseases, defined as conditions that last a year or longer, require ongoing medical attention, restrict daily activities, or both. Recombinant DNA technology advancements have significantly improved healthcare by producing biopharmaceutical proteins used in pharmaceuticals and replacing defective genes with healthy ones through gene therapy, aimed at curing illnesses. For instance, in February 2024, the World Health Organization projected over 35 million new cancer cases by 2050, representing a 77% increase from the estimated 20 million cases in 2022. This increase in chronic diseases is fueling the growth of the recombinant DNA technology market.
What Segments Are Covered In The Recombinant DNA Technology Market Report?
The recombinant DNA technology market covered in this report is segmented as follows:
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Order your report now for swift delivery:
Who Are The Major Players In The Recombinant DNA Technology Market?
The major players operating in the recombinant DNA technology market are Profacgen BioTech Corp., Amgen Inc., Novartis International AG, GenScript Biotech Corporation, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co. Inc., Biogen Inc., GlaxoSmithKline PLC, New England Biolabs Inc., Bayer CropScience, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Moderna Inc., Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc., bluebird bio Inc., Illumina Inc., Qiagen N.V., Lonza Group AG, Bio-Rad Laboratories Inc., Agilent Technologies Inc., Becton Dickinson and Company, Sartorius AG, Abcam PLC, Horizon Discovery Group PLC, Integrated DNA Technologies Inc., Twist Bioscience Corporation, Synthego Corporation, Codex DNA Inc., InvivoGen, Eurofins Scientific SE, Sarepta Therapeutics Inc., Sangamo Therapeutics Inc.
What Are The Emerging Trends In The Recombinant DNA Technology Market?
Technological advancements are a key trend in the recombinant DNA technology market. For instance, in August 2022, Bluebird bio, Inc., a US-based biotechnology company, launched the FDA-approved ZYNTEGLO. This one-time gene therapy treats beta-thalassemia by targeting its genetic cause, giving patients the chance to become independent of regular red blood cell transfusions. This breakthrough reduces the lifelong burden of managing beta-thalassemia.
Which Region Is Projected To Grow Fastest In The Recombinant DNA Technology Market?
In 2024, North America held the largest share in the recombinant DNA technology market. Meanwhile, Asia-Pacific is anticipated to be the fastest-growing region during the forecast period. The report covers regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
What Does The Recombinant DNA Technology Market Report 2025 Offer?
Recombinant DNA technology refers to the process of combining DNA molecules from different sources and inserting them into a host organism to create new genetic combinations beneficial to science, medicine, agriculture, and industry. The technology is significantly used to resolve health issues by creating new medications and vaccines. The Recombinant DNA Technology Market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights:
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Twitter: https://twitter.com/tbrc_info
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model